PODD Insulet Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
19:52
Jun 23
Jun 23
The author screens for low forward PEG ratios among high-growth gainers but does not state a personal position or forward call on any ticker.
LOW
13:12
May 06
May 06
The author mocks the T2 diabetes thesis for PODD, implying the stock is failing and calling it dead tech.
HIGH
13:11
May 06
May 06
The author mocks the T2 diabetes thesis for PODD, implying it is failing and questioning those who believed in it.
HIGH
23:55
Apr 23
Apr 23
Insulet too expensive due to GLP-1.
Insulet is the most declined stock in healthcare and remains too expensive because the GLP-1 drug threat is existential.
MED
About PODD Analyst Coverage
Buzzberg tracks PODD (Insulet) across 3 sources. 0 bullish vs 0 bearish calls from 3 analysts. Sentiment: evenly split. 4 total trade ideas tracked. Latest voices: Minnvestor, TheLAPurchaser, Jim Cramer.